Search Results
#
Progress Update: Regulation and activity of the DUX4 transcription factor
May 20, 2020, 3:24 PM
Dr. Tapscott provides an update on his multi-year grant.
#
Progress Update: Antisense Oligonucleotide – Antibody Conjugates to Treat FSHD
May 20, 2020, 2:41 PM
Dr. Marusak provides an update on progress so far.
#
Dyne Therapeutics Accelerates Programs in FSHD
May 19, 2020, 2:22 PM
Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization University of Mons
#
Fulcrum Therapeutics Update on ReDUX4 Study
May 13, 2020, 1:46 PM
Fulcrum amends their Phase 2b trial, ReDUX4, to extend the trial from 24 to 48 weeks, adds an interim analysis for subjects who underwent their 16-week biopsy as originally planned, and adds a 36-week biopsy for patients who cannot undergo their 16-week biopsy.